Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Share-based Compensation (2016 - 2025)

Medifast (MED) has disclosed Share-based Compensation for 16 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 1.88% year-over-year to $2.2 million, compared with a TTM value of $7.6 million through Dec 2025, up 3.75%, and an annual FY2025 reading of $7.6 million, up 3.75% over the prior year.
  • Share-based Compensation was $2.2 million for Q4 2025 at Medifast, up from $910000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.3 million in Q4 2021 and bottomed at $606000.0 in Q1 2023.
  • Average Share-based Compensation over 5 years is $2.2 million, with a median of $2.3 million recorded in 2021.
  • Peak annual rise in Share-based Compensation hit 258.25% in 2024, while the deepest fall reached 77.35% in 2024.
  • Year by year, Share-based Compensation stood at $3.3 million in 2021, then fell by 10.33% to $2.9 million in 2022, then fell by 18.88% to $2.4 million in 2023, then dropped by 10.91% to $2.1 million in 2024, then rose by 1.88% to $2.2 million in 2025.
  • Business Quant data shows Share-based Compensation for MED at $2.2 million in Q4 2025, $910000.0 in Q3 2025, and $2.6 million in Q2 2025.